OTCMKTS:MYLGF - Mirati Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$6.07
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average Volume355 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
MethylGene, Inc. operates as a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics for cancer and infectious disease.

Receive MYLGF News and Ratings via Email

Sign-up to receive the latest news and ratings for MYLGF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolOTCMKTS:MYLGF
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
OptionableNot Optionable

Mirati Therapeutics (OTCMKTS:MYLGF) Frequently Asked Questions

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the OTCMKTS under the ticker symbol "MYLGF."

Has Mirati Therapeutics been receiving favorable news coverage?

News articles about MYLGF stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Mirati Therapeutics earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the folowing people:
  • Martin Godbout Ph.D, Chairman of the Board (Age 57)
  • Charles M. Baum M.D., Ph.D., President, Chief Executive Officer, Director (Age 55)
  • Mark J. Gergen, Chief Operations Officer, Executive Vice President (Age 51)
  • Rachel W. Humphrey M.D., Chief Medical Officer, Executive Vice President (Age 51)
  • Jamie A. Donadio, Vice President - Finance (Age 38)
  • Henry J. Fuchs M.D., Ph.D., Independent Director (Age 55)
  • Rodney W. Lappe Ph.D., Independent Director (Age 58)
  • Peter A. Thompson M.D., Independent Director (Age 53)

How do I buy shares of Mirati Therapeutics?

Shares of MYLGF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.


MarketBeat Community Rating for Mirati Therapeutics (OTCMKTS MYLGF)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  175
MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe MYLGF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYLGF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by MarketBeat.com Staff

Featured Article: Asset Allocation

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel